Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14-0029-82 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD2 Monoclonal Antibody (RPA-2.10), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The RPA-2.10 monoclonal antibody reacts with human CD2, a 50 kDa cell surface receptor expressed by a majority of thymocytes, all mature T cells and subset of NK cells. CD2 is a ligand for CD58 in the human and is involved in adhesion and activation of T cells. RPA-2.10 blocks mixed lymphocyte reaction. RPA-2.10 crossreacts to non-human primates and pigs. Applications Reported: The RPA-2.10 antibody has been reported for use in flow cytometric analysis, immunoblotting (WB), and immunohistochemical staining of frozen tissue sections. RPA-2.10 has also been reported for use in in vitro blocking of human CD2 (LFA-2). (Please use Functional Grade purified RPA-2.10, Product # 16-0029-81, in functional assays). Applications Tested: This RPA-2.10 antibody has been tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human, Porcine
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- RPA-2.10
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- 4° C
Submitted references Constraints on GPCR Heterodimerization Revealed by the Type-4 Induced-Association BRET Assay.
Multiple Levels of Control Determine How E4bp4/Nfil3 Regulates NK Cell Development.
The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression.
Ebf1 and c-Myb repress rag transcription downstream of Stat5 during early B cell development.
Generation of bivalent chromatin domains during cell fate decisions.
A monoclonal antibody selection for immunohistochemical examination of lymphoid tissues from non-human primates.
RPA-2.10: an anti-CD2 monoclonal antibody that inhibits alloimmune responses and monitors T cell activation.
Felce JH, MacRae A, Davis SJ
Biophysical journal 2019 Jan 8;116(1):31-41
Biophysical journal 2019 Jan 8;116(1):31-41
Multiple Levels of Control Determine How E4bp4/Nfil3 Regulates NK Cell Development.
Kostrzewski T, Borg AJ, Meng Y, Filipovic I, Male V, Wack A, DiMaggio PA, Brady HJM
Journal of immunology (Baltimore, Md. : 1950) 2018 Feb 15;200(4):1370-1381
Journal of immunology (Baltimore, Md. : 1950) 2018 Feb 15;200(4):1370-1381
The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression.
Male V, Nisoli I, Kostrzewski T, Allan DS, Carlyle JR, Lord GM, Wack A, Brady HJ
The Journal of experimental medicine 2014 Apr 7;211(4):635-42
The Journal of experimental medicine 2014 Apr 7;211(4):635-42
Ebf1 and c-Myb repress rag transcription downstream of Stat5 during early B cell development.
Timblin GA, Schlissel MS
Journal of immunology (Baltimore, Md. : 1950) 2013 Nov 1;191(9):4676-87
Journal of immunology (Baltimore, Md. : 1950) 2013 Nov 1;191(9):4676-87
Generation of bivalent chromatin domains during cell fate decisions.
De Gobbi M, Garrick D, Lynch M, Vernimmen D, Hughes JR, Goardon N, Luc S, Lower KM, Sloane-Stanley JA, Pina C, Soneji S, Renella R, Enver T, Taylor S, Jacobsen SE, Vyas P, Gibbons RJ, Higgs DR
Epigenetics & chromatin 2011 Jun 6;4(1):9
Epigenetics & chromatin 2011 Jun 6;4(1):9
A monoclonal antibody selection for immunohistochemical examination of lymphoid tissues from non-human primates.
Kap YS, van Meurs M, van Driel N, Koopman G, Melief MJ, Brok HP, Laman JD, 't Hart BA
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2009 Dec;57(12):1159-67
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2009 Dec;57(12):1159-67
RPA-2.10: an anti-CD2 monoclonal antibody that inhibits alloimmune responses and monitors T cell activation.
Aversa GG, Bishop GA, Suranyi MG, Hall BM
Transplantation proceedings 1987 Feb;19(1 Pt 1):277-8
Transplantation proceedings 1987 Feb;19(1 Pt 1):277-8
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with 0.25 µg of Mouse IgG1 kappa Isotype Control Purified (Product # 14-4714-82) (open histogram) or 0.25 µg of Anti-Human CD2 Purified (filled histogram) followed by Anti-Mouse IgG PE (Product # 12-4012). Cells in the lymphocyte gate were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Type-4 BRET assay applied to known controls. ( A ) The mean Delta BRET eff of type-1 transmembrane protein controls using the FKBP 1 type-4 BRET assay. Only the known dimers CD28 and CD80 exhibited significantly nonzero Delta BRET eff when expressed as homomeric pairs. Dark gray bars indicate like-like pairs. ( B ) The mean Delta BRET eff of type-1 transmembrane protein controls using the FKBP 3 type-4 BRET assay. Delta BRET eff is larger for CD28 and CD80 than with the FKBP 1 approach. ( C ) A histogram of CD2 expression in HEK-293T cells transfected with 1 mu g of differently tagged forms of CD2, as measured by flow cytometry. ( D ) Confocal microscopy of CD28-GFP coexpressed with CD28-FKBP 1/3 in the presence and absence of AP20187. No clear GFP internalization was evident. ( E ) The mean Delta BRET eff of GPCRs of known stoichiometry using the FKBP 3 type-4 BRET assay. For all panels, bars indicate mean +- SD. Probability is indicated for difference from Delta BRET eff = 0; * p < 0.05, *** p < 0.005. All data are the result of n >= 3 independent experiments.